Compare LTC Properties Inc (LTC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs McKesson Corporation — how do they compare? LTC Properties Inc trades at $42.53 (market cap $2.27B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 47.8× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.42%). Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and McKesson Corporation for 74 Days on average.
| LTC | MCK | |
|---|---|---|
Market Cap | $2.27B | $108.46B |
Volume | 574,171 | 712,607 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $995.69 |
52-Week Low | $33.98 | $725.17 |
Typical Hold Time | 88 Days | 74 Days |
Enterprise Value | $3.01B | $115.00B |
Dividend Yield | 5.42% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.46, up 1.55% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT demonstrates strong fundamentals with 61.72% gross margins and consistent dividend payments of $0.19 monthly. Recent acquisitions totaling $160 million in senior housing properties signal aggressive growth strategy, though cash flow trends show significant investing outflows. Analyst consensus targets $49.67 with 32% buy ratings amid balanced risk-reward outlook.
LTC presents a balanced opportunity with steady income from monthly dividends and demographic tailwinds in senior housing, offset by execution risks from rapid portfolio transformation and rising interest rate sensitivity. The stock trades at reasonable valuations (P/E 15.02) but faces headwinds from its SHOP transition strategy and macroeconomic pressures on REIT valuations.
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
